Literature DB >> 11257346

Inactivated poliovirus vaccine and the final stages of poliovirus eradication.

T Hovi1.   

Abstract

The use of the inactivated poliovirus vaccine (IPV) will increase before and probably also after the global eradication of the wild type poliovirus. Before eradication, the switch from the use of oral poliovirus vaccine (OPV) to IPV has been due to the better safety record of IPV. Introduction of IPV in the regular immunisation schedules is made easier by the development of several combination vaccines, including IPV. Maternal antibodies and young age, often considered problematic for early initiation of IPV schedules, did not compromise optimal maintenance of seropositivity during infancy or long-term persisting antibody levels in our studies. OPV-derived, potentially pathogenic and transmissible poliovirus strains, excreted by some individuals for years, may present a problem for a blunt stopping of all polio immunisations after eradication. Our recent results suggest that locally excreted IgA might have a role in the elimination of poliovirus infection in the intestinal tissues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257346     DOI: 10.1016/s0264-410x(00)00515-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.

Authors:  James T Gaensbauer; Chris Gast; Ananda S Bandyopadhyay; Miguel O'Ryan; Xavier Saez-Llorens; Luis Rivera; Eduardo Lopez-Medina; Mario Melgar; William C Weldon; M Steven Oberste; Ricardo Rüttimann; Ralf Clemens; Edwin J Asturias
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

Review 3.  Epitope mapping: the first step in developing epitope-based vaccines.

Authors:  Jonathan M Gershoni; Anna Roitburd-Berman; Dror D Siman-Tov; Natalia Tarnovitski Freund; Yael Weiss
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.